Comprehensive Analysis of Bioinformatics and System Biology Reveals the Association Between Girdin and Hepatocellular Carcinoma

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Dec 13

PMID 39671369

Authors

Tengda Huang

Hongying Chen

Hongyuan Pan

Tian Wu

Xiangyi Ren

Liwen Qin

Kefei Yuan

Fang He

Affiliations

Soon will be listed here.

Abstract

Introduction: Hepatocellular carcinoma is one of the leading causes of cancer-related mortality worldwide. The actin-binding protein Girdin is overexpressed in various tumors, promoting tumorigenesis and progression. However, the exact mechanisms by which Girdin regulates liver cancer remain poorly understood.

Methods: This study comprehensively analyzed the expression level of Girdin in liver cancer and adjacent tissue, along with the correlation between Girdin expression and the clinical characteristics and prognosis of liver cancer. The analysis integrated data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Clinical Proteomic Tumor Analysis Consortium (CPTAC) database. Subsequently, Girdin expression was knocked down to elucidate its role in the progression of liver cancer. Transcriptome sequencing was employed to investigate the mechanistic underpinnings of Girdin's regulatory impact on liver cancer. Additionally, the Comparative Toxicogenomics Database (CTD) was utilized to identify potential drugs or molecules for liver cancer treatment.

Results: The findings revealed elevated Girdin expression in liver cancer tissues, and heightened Girdin expression correlating with adverse clinical features and prognosis. Silencing of Girdin markedly impeded the proliferation and migration of hepatocellular carcinoma cells. Moreover, transcriptome sequencing demonstrated that silencing Girdin led to differential expression of 176 genes and inhibition of the PI3K/Akt signaling pathway, as well as its upstream pathways-Cytokine-cytokine receptor interaction and Chemokine signaling pathway. Ultimately, we propose that Imatinib Mesylate, Orantinib, Resveratrol, Sorafenib, and Curcumin may interact with Girdin, potentially contributing to the treatment of liver cancer.

Conclusion: This study reveals the association between Girdin and hepatocellular carcinoma, providing novel clues for future research and treatment of hepatocellular carcinoma.

References

Yu L, Sun Y, Li J, Wang Y, Zhu Y, Shi Y . Silencing the Girdin gene enhances radio-sensitivity of hepatocellular carcinoma via suppression of glycolytic metabolism. J Exp Clin Cancer Res. 2017; 36(1):110. PMC: 5558715. DOI: 10.1186/s13046-017-0580-7. View

Wang X, Ji C . Construction of a prognostic risk model based on apoptosis-related genes to assess tumor immune microenvironment and predict prognosis in hepatocellular carcinoma. BMC Gastroenterol. 2022; 22(1):400. PMC: 9414141. DOI: 10.1186/s12876-022-02481-w. View

Huang S, Dong C, Zhang J, Fu S, Lv Y, Wu J . A comprehensive prognostic and immunological analysis of ephrin family genes in hepatocellular carcinoma. Front Mol Biosci. 2022; 9:943384. PMC: 9424725. DOI: 10.3389/fmolb.2022.943384. View

Rauf A, Imran M, Butt M, Nadeem M, Peters D, Mubarak M . Resveratrol as an anti-cancer agent: A review. Crit Rev Food Sci Nutr. 2016; 58(9):1428-1447. DOI: 10.1080/10408398.2016.1263597. View

Kar S, Samii A, Bertalanffy H . PTEN/PI3K/Akt/VEGF signaling and the cross talk to KRIT1, CCM2, and PDCD10 proteins in cerebral cavernous malformations. Neurosurg Rev. 2014; 38(2):229-36. DOI: 10.1007/s10143-014-0597-8. View

Lu Y, Wang S, Chi T, Zhao Y, Guo H, Wang H . DNA damage repair-related gene signature for identifying the immune status and predicting the prognosis of hepatocellular carcinoma. Sci Rep. 2023; 13(1):18978. PMC: 10624694. DOI: 10.1038/s41598-023-45999-z. View

Chandrashekar D, Bashel B, Balasubramanya S, Creighton C, Ponce-Rodriguez I, Chakravarthi B . UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(8):649-658. PMC: 5516091. DOI: 10.1016/j.neo.2017.05.002. View

Cao F, Yang D, Tang F, Lu C, He X, Chen S . Girdin Promotes Tumorigenesis and Chemoresistance in Lung Adenocarcinoma by Interacting with PKM2. Cancers (Basel). 2022; 14(22). PMC: 9688487. DOI: 10.3390/cancers14225688. View

Sun T, Bi F, Liu Z, Yang Q . TMEM119 facilitates ovarian cancer cell proliferation, invasion, and migration via the PDGFRB/PI3K/AKT signaling pathway. J Transl Med. 2021; 19(1):111. PMC: 7968362. DOI: 10.1186/s12967-021-02781-x. View

10.

Kim D, Langmead B, Salzberg S . HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015; 12(4):357-60. PMC: 4655817. DOI: 10.1038/nmeth.3317. View

11.

Enomoto A, Ping J, Takahashi M . Girdin, a novel actin-binding protein, and its family of proteins possess versatile functions in the Akt and Wnt signaling pathways. Ann N Y Acad Sci. 2006; 1086:169-84. DOI: 10.1196/annals.1377.016. View

12.

Huang T, Jiang N, Song Y, Pan H, Du A, Yu B . Bioinformatics and system biology approach to identify the influences of SARS-CoV-2 on metabolic unhealthy obese patients. Front Mol Biosci. 2023; 10:1274463. PMC: 10591333. DOI: 10.3389/fmolb.2023.1274463. View

13.

Yu M, Qi B, Xiaoxiang W, Xu J, Liu X . Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K/Akt/NF-κB pathway. Biomed Pharmacother. 2017; 90:677-685. DOI: 10.1016/j.biopha.2017.04.001. View

14.

Yamamura Y, Asai N, Enomoto A, Kato T, Mii S, Kondo Y . Akt-Girdin signaling in cancer-associated fibroblasts contributes to tumor progression. Cancer Res. 2015; 75(5):813-23. DOI: 10.1158/0008-5472.CAN-14-1317. View

15.

Liao W, Du J, Li L, Wu X, Chen X, Feng Q . CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma. J Exp Clin Cancer Res. 2023; 42(1):125. PMC: 10193609. DOI: 10.1186/s13046-023-02699-w. View

16.

Davis A, Grondin C, Johnson R, Sciaky D, Wiegers J, Wiegers T . Comparative Toxicogenomics Database (CTD): update 2021. Nucleic Acids Res. 2020; 49(D1):D1138-D1143. PMC: 7779006. DOI: 10.1093/nar/gkaa891. View

17.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

18.

Fruman D, Meyers R, Cantley L . Phosphoinositide kinases. Annu Rev Biochem. 1998; 67:481-507. DOI: 10.1146/annurev.biochem.67.1.481. View

19.

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D . Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006; 66(24):11851-8. DOI: 10.1158/0008-5472.CAN-06-1377. View

20.

Hennessy B, Smith D, Ram P, Lu Y, Mills G . Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005; 4(12):988-1004. DOI: 10.1038/nrd1902. View